Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tissue non-specific alkaline phosphatase (TNAP) is a crucial ectoenzyme involved primarily in skeletal mineralization through its ability to degrade inhibitors like PPi. Its activity extends beyond bones into neural tissues where it influences cell differentiation/migration. Loss-of-function mutations cause hypophosphatasia with broad clinical manifestations affecting bones/teeth/neural function. Due to its central role both physiologically and pathologically—including potential involvement in vascular calcification—TNAP remains an important target for research into metabolic bone diseases as well as extra-skeletal disorders linked to abnormal phosphate metabolism or inflammation modulation.
Inhibition of TNAP activity to treat diseases such as hypophosphatasia or modulation of its activity for other therapeutic applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tissue Non-Specific Alkaline Phosphatase (TNAP).